Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
BACKGROUNDAn increase in intrahepatic triglyceride (IHTG) is the hallmark feature of nonalcoholic fatty liver disease (NAFLD) and is decreased by weight loss. Hepatic de novo lipogenesis (DNL) contributes to steatosis in individuals with NAFLD. The physiological factors that stimulate hepatic DNL and the effect of weight loss on hepatic DNL are not clear.METHODSHepatic DNL, 24-hour integrated plasma insulin and glucose concentrations, and both liver and whole-body insulin sensitivity were determined in individuals who were lean (n = 14), obese with normal IHTG content (n = 26), or obese with NAFLD (n = 27). Hepatic DNL was assessed using the deuterated water method corrected for the potential confounding contribution of adipose tissue DNL. Liver and whole-body insulin sensitivity was assessed using the hyperinsulinemic-euglycemic clamp procedure in conjunction with glucose tracer infusion. Six subjects in the obese-NAFLD group were also evaluated before and after a diet-induced weight loss of 10%.RESULTSThe contribution of hepatic DNL to IHTG-palmitate was 11%, 19%, and 38% in the lean, obese, and obese-NAFLD groups, respectively. Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations. Weight loss decreased IHTG content, in conjunction with a decrease in hepatic DNL and 24-hour plasma glucose and insulin concentrations.CONCLUSIONSThese data suggest hepatic DNL is an important regulator of IHTG content and that increases in circulating glucose and insulin stimulate hepatic DNL in individuals with NAFLD. Weight loss decreased IHTG content, at least in part, by decreasing hepatic DNL.TRIAL REGISTRATIONClinicalTrials.gov NCT02706262.FUNDINGThis study was supported by NIH grants DK56341 (Nutrition Obesity Research Center), DK20579 (Diabetes Research Center), DK52574 (Digestive Disease Research Center), and RR024992 (Clinical and Translational Science Award), and by grants from the Academy of Nutrition and Dietetics Foundation, the College of Natural Resources of UCB, and the Pershing Square Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, DNL has been associated with hepatic and whole-body IR (glucose metabolism),24,25 suggesting that IR may accelerate hepatic DNL.25”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [25]
In the citing paper
“In a well-designed study by Smith et al. [50], the contribution of hepatic DNL to intrahepatic TG palmitate was 11%, 19%, and 38% in the lean, obese, and obese-MASLD groups, respectively.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [50]
In the citing paper
“Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007) · Behavior Research Methods · doi:10.3758/bf03193146 · Cited by 65,971
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 5×
“First, the long (3-5 week) duration of D2O tracer administration in our study accounted for labelling of the liver TG pools that turn over slowly (12) and provided an integrated assessment of DNL during daily fasting and fed conditions over several weeks.”
BackgroundMethodResultInfluentialA new predictive equation for resting energy expenditure in healthy individuals
Mifflin, M., St Jeor, S., Hill, L., Scott, B., Daugherty, S., & Koh, Y. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.2.241 · Cited by 2,544 · cited 2×
“The initial daily energy content of the diet provided 75% of estimated energy requirements (54); subsequent meals and energy”
BackgroundMethodObesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
Self-citationNonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 1×
“Although the mechanism(s) responsible for the increase in hepatic DNL in people with NAFLD is not known, it is possible that increases in circulating insulin and glucose associated with hepatic and whole-body insulin resistance are involved in stimulating hepatic DNL because insulin and glucose activate SREBP-1c and C…”
Background
Research works printed but not linked: 2
- 10.1172/JCI22422 · DOI · Paper page
- 10.1016/S1097-2765(05)00010-9 · doi:10.1016/s1097-2765(05)00010-9 · Paper page
Cited by
Items 301–400 of 770
Gijbels, A., Erdõs, B., Trouwborst, I., Jardon, K. M. C., Adriaens, M. E., Goossens, G. H., Blaak, E. E., Feskens, E. J. M., & Afman, L. A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02188-0 · Cited by 26
“Higher hepatic IR, as measured with the gold-standard hyperinsulinemic-euglycemic clamp method, has indeed been positively associated to the relative contribution of hepatic DNL to plasma TAG in TAG-rich lipoproteins, indicating elevated DNL [34].”
MethodNon-Alcoholic Fatty Liver Disease (NAFLD) Management in the Community
Park, Y. B., Ko, K. S., & Rhee, B. D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062758 · Cited by 25
“This resulted in a smaller reduction in blood β -hydroxy butyrates (ketones) [16].”
Lipogenesis and MASLD: re-thinking the role of SREBPs
Nakagawa, H. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04052-w · Cited by 25
“Indeed, insulin resistance has been demonstrated to drive hepatic DNL in patients with MASLD (Smith et al. 2020).”
Liu, X., Jiang, Y., Ye, J., & Wang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.999412 · Cited by 21
“The incidence of liver DNL was substantially increased in patients with NAFLD (38, 39).”
BackgroundChronotherapy with a glucokinase activator profoundly improves metabolism in obese Zucker rats
Kroon, T., Hagstedt, T., Alexandersson, I., FERM, A., Petersson, M., Maurer, S., Zarrouki, B., Wallenius, K., Oakes, N. D., & Boucher, J. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abh1316 · Cited by 19
“Enhanced glycogen storage would divert glucose away from DNL and most likely contributed to the hepatic TG lowering effect of GKA during feeding only (fig.”
BackgroundInfluentialZhang, L., Hu, W., Qiu, Z., Li, Z., & Bian, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00179 · Cited by 17
Cao, Y., Fang, X., Sun, M., Zhang, Y., Shan, M., Lan, X., Zhu, D., & Luo, H. (2023) · Phytotherapy Research · doi:10.1002/ptr.7932 · Cited by 18
Global 13C tracing and metabolic flux analysis of intact human liver tissue ex vivo
Grankvist, N., Jönsson, C., Hedin, K., Sundqvist, N., Sandström, P., Björnsson, B., Begzati, A., Mickols, E., Artursson, P., Jain, M., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01119-3 · Cited by 21
“For example, 13 C tracing has been used to determine differences in hepatic metabolism of fructose and glucose 4 , and deuterated water ( 2 H 2 O) has been used to probe de novo lipogenesis 5 by measuring 2 H incorporation into blood lipids.”
MethodPhysiological and pathophysiological actions of insulin in the liver
Kubota, N., Kubota, T., & Kadowaki, T. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej24-0192 · Cited by 19
“…reported to be inversely correlated with hepatic and whole-body insulin sensitivity and directly correlated with the plasma insulin concentrations [114], it is possible that enhanced hepatic insulin signaling resulting from hyperinsulinemia in cases of MASLD might directly promote hepatic de novo…”
Xu, X., Li, H., Lin, H., Li, Q., Liu, Y., Huang, W., Yang, J., Li, N., Gao, Z., Wang, S., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001429 · Cited by 16
“[11] Notably, palmitic acid (PA, C16:0) and other saturated FFA (SFFA) exhibit more severe lipotoxicity than unsaturated FFA (USFFA), as they induce hepatocyte lipoapoptosis, [12 – 14] leading to the release of danger-associated molecular patterns (DAMPs) which can induce liver inflammation,…”
Endocrine Disorders and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review
Betlejewska, J., Hubska, J., Roszkowska, Z., Maciejczyk, A., Bachurska, D., Domański, J., Miarka, M., Raszeja‐Wyszomirska, J., Bobrowicz, M., & Ambroziak, U. (2025) · Biomedicines · doi:10.3390/biomedicines13102500 · Cited by 20
“In addition, IR impairs AT function, leading to the secretion of pro-inflammatory cytokines [21,22].”
Extrahepatic factors in hepatic immune regulation
Zhang, S., Lu, S., & Li, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.941721 · Cited by 18
Jahangiri, S., Malek, M., Kalra, S., & Khamseh, M. E. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01481-7 · Cited by 23
“Changes in body composition influence the risk of developing T2DM through a variety of mechanisms such as insulin resistance, metabolic dysfunction, and de novo lipogenesis in ectopic tissues [14, 15].”
BackgroundJin, X., Xu, J., & Weng, X. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1428593 · Cited by 18
Liver metabolism in human MASLD: A review of recent advancements using human tissue metabolomics
Flam, E. L., Haas, J. T., & Staels, B. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119054 · Cited by 19
Mungamuri, S. K., Sinha, S. N., & Javvadi, Y. (2020) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2020035839 · Cited by 19
Fan, L., Niu, H., Zhao, L., Yao, R., He, X., Lu, B., & Pang, Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112697 · Cited by 16
Smith, K., Dennis, K. M. J. H., & Hodson, L. (2025) · Experimental Physiology · doi:10.1113/ep092001 · Cited by 22
“Thus, when DNL is upregulated constitutively, as seen in people with insulin resistance (Pramfalk et al., 2016) and MASLD (Lambert et al., 2014; Smith et al., 2020), this can lead to reduced FA oxidation (Pramfalk et al., 2016).”
Comparison of the Lipidomic Signature of Fatty Liver in Children and Adults: A Cross‐Sectional Study
Mann, J. P., Jenkins, B., Furse, S., Snowden, S. G., Alisi, A., Draijer, L. G., Karnebeek, K., Kelly, D. A., Koot, B. G. P., Mosca, A., et al. (2022) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003418 · Cited by 15
Nudix hydrolase NUDT19 regulates mitochondrial function and ATP production in murine hepatocytes
Görigk, S., Ouwens, D. M., Kuhn, T., Altenhofen, D., Binsch, C., Damen, M., Khuong, J. M.-A., Kaiser, K., Knebel, B., Vogel, H., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159153 · Cited by 15
Su, Y., Kang, Y., Yi, J., Lin, Q., Zhang, C., Lin, Z., Yan, Z., Qu, J., & Liu, J. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/2122563 · Cited by 18
“To date, the Chinese herbal extracts were shown to relieve NAFLD in numerous aspects, such as lipid metabolism abnormalities, endoplasmic reticulum stress, oxidative stress, inflammation, hepatocyte apoptosis, and necrosis [3, 4].”
BackgroundTsamos, G., Vasdeki, D., Koufakis, T., Michou, V., Makedou, K., & Tzimagiorgis, G. (2023) · Metabolites · doi:10.3390/metabo13040517 · Cited by 16
“In addition, other metabolic disturbances, such as hyperinsulinemia and hyperglycemia, promote increased liver conversion of carbohydrates into fatty acids through de novo lipogenesis [15].”
BackgroundKloock, S., Haerting, N., Herzog, G., Oertel, M., Geiger, N., Geier, A., Sequeira, V., Nickel, A. G., Kohlhaas, M., Faßnacht, M., et al. (2024) · Nutrients · doi:10.3390/nu16060904 · Cited by 16
“IR leads to lipolysis in white adipose tissue with subsequent uptake of fatty acids in the liver [9] and an increased hepatic DNL [5,10].”
BackgroundLutkewitte, A. J., Singer, J., Shew, T. M., Martino, M. R., Hall, A. M., He, M., & Finck, B. N. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101204 · Cited by 15
Opazo-Ríos, L., Soto‐Catalán, M., Lázaro, I., Sala‐Vila, A., Jiménez-Castilla, L., Orejudo, M., Moreno, J. A., Egido, J., & Mas, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073965 · Cited by 16
“Of interest, the lipid profile associated with BTBR ob/ob mice showed an enrichment in de novo synthesized lipids (C16:0, C18:0, C16:1n-7 and C18:1n-9cis), a picture similar to that observed in subjects with MAFLD [35].”
ResultNucleoside diphosphate kinases 1 and 2 regulate a protective liver response to a high-fat diet
Iuso, D., Garcia-Saez, I., Couté, Y., Yamaryo-Botté, Y., Boeri Erba, E., Adrait, A., Zeaiter, N., Tokarska-Schlattner, M., Jilkova, Z. M., Boussouar, F., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh0140 · Cited by 14
Tao, S., Lei, Y., Tan, Y.-M., Yang, Y., & Xie, W. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1476419 · Cited by 18
Qin, L.-N., Yu, Y., Ma, L., & Yu, R. (2025) · Molecules and Cells · doi:10.1016/j.mocell.2025.100216 · Cited by 14
“…ng g r o w t h f a c t o r β ; N r f - 2 , nu c l ea r f a c t o r e r y t h r o i d 2 -r e l a t ed f a c t o r 2 ; H O - 1 , he m e o xy gena s e 1 ; liver, where they undergo re-esterification into triglycerides, resulting in increased lipid droplet deposition in the liver (Smith et al., 2020).”
Guo, Y., Zhang, N., & Pei, D. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1645298 · Cited by 18
Qiu, Y., Laguna, J. C., Alegret, M., & Vilà, L. (2026) · Nutrients · doi:10.3390/nu18040679 · Cited by 16
“In these patients, DNL may contribute to as much as 40% of hepatic lipid accumulation under postprandial conditions [41].”
Ramos-Román, M. A., Syed‐Abdul, M. M., Casey, B. M., Alger, J. R., Liu, Y., & Parks, E. J. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100288 · Cited by 17
“(38), have demonstrated a graded increase in DNL with increasing levels of IHTG in lean and obese subjects without NAFLD, as well as in obese subjects with NAFLD.”
BackgroundmTORC1 syndrome (TorS): unified paradigm for diabetes/metabolic syndrome
Bar‐Tana, J. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.01.001 · Cited by 17
“Also, liver steatosis of T2D/MetS reflects insulin-responsive hepatic lipogenesis and triglyceride synthesis [11,12].”
BackgroundSyed‐Abdul, M. M., Moore, M. P., Wheeler, A. A., Ganga, R., Diaz‐Arias, A. A., Petroski, G. F., Rector, R. S., Ibdah, J. A., & Parks, E. J. (2023) · Journal of Nutrition · doi:10.1016/j.tjnut.2023.09.018 · Cited by 16
Choi, E., Tovar, A. R., He, Z., Rodriguez, D. S., Vos, M. B., Arora, S., & Fadoju, D. (2024) · Children · doi:10.3390/children11030275 · Cited by 19
“…has not been any pharmacotherapeutic agent approved by a regulatory agency for the treatment of pediatric The pathophysiology of MASLD in children involves a cycle of increased de novo lipogenesis (DNL) and intrahepatic triglyceride content with increased plasma glucose and insulin resistance [18].”
Lifestyle interventions affecting hepatic fatty acid metabolism
Parry, S. A., Turner, M. C., & Hodson, L. (2020) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000687 · Cited by 17
Grocic, M., Nguyen, M., & Sanyal, A. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70662 · Cited by 19
Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?
Neokosmidis, G., Cholongitas, Ε., & Τζιόμαλος, Κ. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i39.6522 · Cited by 15
Lundsgaard, A., Bojsen-Møller, K. N., & Kiens, B. (2023) · Advances in Nutrition · doi:10.1016/j.advnut.2023.08.005 · Cited by 15
“Created with biorender.com. and 43% in obese individuals with steatosis [93,94].”
BackgroundCottier, K. E., Bhalerao, D., Lewis, C., Gaffney, J., & Heyward, S. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-42785-9 · Cited by 15
“FASN, which is likewise involved in DNL, was also differentially regulated here.”
InfluentialThe metabolic profiles and body composition of non-obese metabolic associated fatty liver disease
Zhang, Y., Xiang, L.-L., Qi, F., Cao, Y.-T., Zhang, W., Lv, T.-S., & Zhou, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1322563 · Cited by 16
Some paradoxes and unresolved aspects of hepatic de novo lipogenesis
Jones, J. G. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00020-7 · Cited by 16
Playing Jekyll and Hyde—The Dual Role of Lipids in Fatty Liver Disease
Molenaar, M. R., Penning, L. C., & Helms, J. B. (2020) · Cells · doi:10.3390/cells9102244 · Cited by 14
“In another study, DNL contributed to 11, 20 or 40% of the total hepatic lipid accumulation in cohorts of healthy, obese or obese-NAFL individuals, respectively [49].”
BackgroundMethodMa, D., Zeng, J., Huang, B., Yan, F., Ye, J., Chen, Y., Zeng, X., Zheng, X. S., Xiao, F., Lin, M., et al. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-02011-0 · Cited by 14
Zani, S. C. D. C., Wang, R., Veida-Silva, H., Clugston, R. D., Yue, J. T. Y., Mori, M. A. S., Wu, J., & Chan, C. B. (2023) · Metabolites · doi:10.3390/metabo13020174 · Cited by 14
“DNL produces fatty acids from non-lipid precursors such as glucose or fructose and is increased in IR states [3], and plays an important role in NAFLD [4].”
BackgroundA bibliometric analysis and visualization of nonalcoholic fatty liver disease from 2012 to 2021
Li, Z., Cao, S., Zhao, S., & Kang, N. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01023-2 · Cited by 15
“For example, University of California System, Harvard University, University of California at San Diego and Shanghai Jiao Tong University have made a lot of research output [25–29].”
BackgroundBiomimetic MicroRNAs‐Selenium‐Nanocomposites for Targeted and Combined Hyperlipidemia Therapy
Li, T., Liu, L., Zhu, K., Yun, L., Huang, X., Dong, Y., & Huang, J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400064 · Cited by 14
Metabolic Signatures in Lean MASLD: Current Insights and Future Directions
Babu, A. F. (2025) · Metabolites · doi:10.3390/metabo15090583 · Cited by 20
“Insulin resistance in lean MASLD activates lipogenic transcription factors—SREBP-1c and ChREBP—enhancing de novo lipogenesis, compounded by BA dysmetabolism and cholestasis, as evidenced by elevated alkaline phosphatase and gamma-glutamyl transferase [59].”
Ward, C., Peng, L., Yuen, S., Chang, M., Karapetyan, R., Nyangau, E., Mohammed, H., Palacios, H. H., Ziari, N., Joe, L. K., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031073 · Cited by 14
Self-citationMetabolic Disturbance of High-Saturated Fatty Acid Diet in Cognitive Preservation
Rivas-Domínguez, A., Mohamed-Mohamed, H., Jiménez-Palomares, M., García‐Morales, V., Martínez-López, L., Orta, M. L., Ramos‐Rodríguez, J. J., & Bermúdez, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098042 · Cited by 13
“In this sense, insulin resistance promotes de novo hepatic lipogenesis and consequently increases VLDL and LDL [48,49], much like those found in LDLR−/−-HFD animals.”
Regulation of hepatic lipogenesis by asymmetric arginine methylation
Han, H.-S., Choi, B. H., Jang, S. Y., Choi, S., Hwang, G., & Koo, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155938 · Cited by 12
Ning, Q., Zheng, K., Yan, J., & Zhu, C. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1429413 · Cited by 14
Zhang, Z., He, Y., Zhao, M., He, X., Zhou, Z., Yue, Y., Shen, T., Liu, J., Zhang, G., & Zhang, Y. (2024) · ACS Omega · doi:10.1021/acsomega.4c07463 · Cited by 13
De novo lipid synthesis in cardiovascular tissue and disease
Khan, T. J., Semenkovich, C. F., & Zayed, M. A. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119066 · Cited by 13
“Lipidomic analysis of hearts harvested from rats that sustained an acute myocardial infarction (MI) show significant alterations in 153 polar lipid species, including PCs and lysoPCs [72].”
Lambda-cyhalothrin induces lipid accumulation in mouse liver is associated with AMPK inactivation
Yang, D., Sun, X., Wei, X., Zhang, B., Fan, X., Du, H., Zhu, R., Oh, Y., & Gu, N. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113563 · Cited by 14
Taya, N., Katakami, N., Omori, K., Hosoe, S., Watanabe, H., Takahara, M., Miyashita, K., Nishizawa, H., Konya, Y., Obara, S., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13924 · Cited by 11
Khandelwal, M., Krishna, G., Ying, Z., & Gómez‐Pinilla, F. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166728 · Cited by 15
Shirkhani, S., Marandi, S. M., Nasr‐Esfahani, M. H., & Kim, S. K. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0265 · Cited by 15
“IR plays a pivotal role in NALFD via DNL which is highly prevalent in individuals with T2DM [38].”
Maffeis, C., Piona, C. A., Morandi, A., Marigliano, M., Morotti, E., Mancioppi, V., Caiazza, E., Zusi, C., Emiliani, F., Mantovani, A., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15961 · Cited by 12
Kiya, M., Tamura, Y., Takeno, K., Someya, Y., Kakehi, S., Sato, M., Yamasaki, N., Kadowaki, S., Suzuki, R., Furukawa, Y., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab037 · Cited by 14
Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis
Chung, K. W., Cho, Y. E., Kim, S.-J., & Hwang, S. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01379-1 · Cited by 11
Extracellular Vesicles in Pathogenesis and Treatment of Metabolic Associated Fatty Liver Disease
Sun, J., Zhang, D., & Li, Y. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.909518 · Cited by 14
Thilakarathna, W. P. D. W., & Rupasinghe, H. P. V. (2024) · Molecules · doi:10.3390/molecules29030709 · Cited by 12
“Insulin resistance in the adipose tissue can impair glucose uptake [72], increasing the circulating glucose that can induce hepatic TG accumulation by upregulating DNL [73].”
BackgroundGarcía‐Escobar, E., Valdés, S., Soriguer, F., Vendrell, J. J., Urrutia-Etxebarria, I. M., Maldonado‐Araque, C., Ortega, E., Ocón, P., Montanya, E., Menéndez, E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95546-x · Cited by 13
Fahlbusch, P., Nikolic, A., Hartwig, S., Jacob, S., Kettel, U., Koellmer, C., Al‐Hasani, H., Lehr, S., Müller‐Wieland, D., Knebel, B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126873 · Cited by 12
“The development of hepatic steatosis is mainly driven by SREBP-1c [6,14], supported by the observation that up to 38% of hepatic triglycerides are derived from DNL in this pathology [15].”
BackgroundKyhl, L. K., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Nielsen, S. F. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120551 · Cited by 16
Genetic Predisposition to MASLD: Potential for Therapeutic Management
Karapanagiotidi, F., Boutari, C., & Sinakos, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041933 · Cited by 10
“Although increased de novo lipogenesis is proposed as one of the mechanisms resulting in MASLD [9,10], some evidence suggests that this is not the case in PNPLA3 I148M carriers.”
Kyhl, L. K., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Nielsen, S. F. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.05.015 · Cited by 10
Klein, R. J., Rodriguez, G. M. V., Rotman, Y., & Brown, R. J. (2023) · Liver International · doi:10.1111/liv.15707 · Cited by 10
“Sources of hepatic TG include re-esterification of FFA derived from adipose tissue lipolysis and, to a lesser degree, dietary lipids and hepatic DNL. 13 Hepatic TGs are depleted by β - oxidation of FFA used for energy, or by secretion of TG into the circulation as VLDL. Hepatic steatosis reflects an imbalance between…”
BackgroundInfluentialZhang, Q., Dong, Y., & Fan, J. (2023) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2023.12.007 · Cited by 11
Pinheiro, F. I., Araújo-Filho, I., Rêgo, A. C. M., de Azevedo, E. P., Cobucci, R. N., & Gúzen, F. P. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102250 · Cited by 10
Deng, S., Ge, Y., Zhai, Z., Liu, H., Zhang, X., Chen, Y., Yang, Y., & Wu, Z. (2024) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2024.109635 · Cited by 10
Zhang, J., Li, Y., Liu, Y., Ma, N., Qian, S., Chen, Y., Duan, Y., Xiang, X., & He, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01267-9 · Cited by 11
“Patients with insulin resistance or type 2 diabetes mellitus (T2DM) tend to have hyperinsulinemia and hyperglycemia, promoting the hepatic conversion of carbohydrates into fatty acids by DNL [20].”
BackgroundCao, C., Huang, M., Han, Y. Y., Zhang, X., Hu, H., & Wang, Y. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01472-z · Cited by 11
“Concurrently, insulin resistance, often associated with increased adiposity, promotes de novo lipogenesis in the liver, further exacerbating lipid deposition [27, 28].”
BackgroundHigh-fat-diet-induced hepatic insulin resistance per se attenuates murine de novo lipogenesis
Goedeke, L., Strober, J. W., Suh, R., Paolella, L. M., Li, X., Rogers, J. C., Petersen, M. C., Nasiri, A. R., Casals, G., Kahn, M., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111175 · Cited by 15
Angelini, G., Russo, S. L. M. L., Carli, F., Infelise, P., Panunzi, S., BERTUZZI, A., Caristo, M. E., Lembo, E., Calce, R., Bornstein, S. R., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202402108r · Cited by 13
“19 In line with the reduction of hepatic steatosis showed by histological analysis, we observed a decrease in the four key rate-limiting enzymes of DNL, namely ATP-citrate lyase (ACLY), acetyl-CoA carboxylase 1 (ACC1), fatty acid synthase (FASN), and Diacylglycerol acyltransferase (DGAT), and an…”
Mouskeftara, T., Kalopitas, G., Liapikos, T., Arvanitakis, K., Theocharidou, E., Germanidis, G. S., & Gika, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313067 · Cited by 11
Fodor, L., Belčić, V., Korbar, A. O., Ćurković, S., Vujičić, B., Gulin, T., Muslim, J., Gulin, M., Grgurević, M., & Ćuti, E. Ć. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247717 · Cited by 12
“This dysregulation of organelles triggers the release of excess ROS and pro-inflammatory signals, contributing to systemic inflammation [66,67].”
Salazar, M. A., Reyes, S. E. O., Estévez, A. M., Lobos, J. A. S., Aldecoa-Castillo, J. M. D., Aguas, J. C. C., Alaniz-Monreal, S., Rodríguez, J. A. N., & Sánchez, D. M. F. A. (2025) · Medicina · doi:10.3390/medicina61010088 · Cited by 13
“One of the molecular mechanisms by which insulin resistance contributes to the development of MASLD and its progression to MASH is the release of molecules that perpetuate low-grade inflammation, such as IL-6, CCL2/MCP-1, and CCL19 [58–61].”
Liu, W., Li, X., Ling, C., & Xiao, L. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01891-7 · Cited by 10
“However, insulin resistance (IR) is one of the key events in T2DM and MASLD [36].”
Luque-Urbano, M. R., Fernández‐Ramos, D., Lopitz‐Otsoa, F., de Juan, V. G., Bizkarguenaga, M., Castro-Espadas, L., Hermoso-Martínez, U., Barbier‐Torres, L., Lu, S. C.-L., Millet, Ó., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100794 · Cited by 17
“Overproduction of VLDL in circulation has been observed in metabolic dysfunction-associated steatotic liver disease (MASLD) patients and is thought to be partially driven by increased de novo lipogenesis (DNL), which promotes hepatic TG synthesis (6, 7).”
Wu, J., Yu, W., Huang, L., Hou, S., Huang, Y., Huang, Z., Dai, Z., Yin, J., & Nie, Z. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03974-0 · Cited by 11
“Conversely, changes in blood glucose levels directly affect the hepatic lipid metabolism [26].”
InfluentialRole of acetylation in nonalcoholic fatty liver disease: a focus on SIRT1 and SIRT3
Nassir, F. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00017 · Cited by 10
“Insulin resistance increases hepatic DNL, reduces adipose tissue insulin sensitivity, and increases the flux of FAs to the liver [15].”
BackgroundCommon Pathogenetic Pathways of Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Giannopoulos, C., Tzima, I. G., Tentolouris, N., & Vasileiadis, I. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230216112032 · Cited by 14
Heterogeneity in the effect of marked weight loss on metabolic function in women with obesity
Mittendorfer, B., Kayser, B. D., Yoshino, M., Yoshino, J., Watrous, J. D., Jain, M., Eagon, J. C., Patterson, B. W., & Klein, S. (2023) · JCI Insight · doi:10.1172/jci.insight.169541 · Cited by 10
“(18, 19) in Non-responders were similar to values we have previously Figure 2.”
Self-citationRaspberry ketone ameliorates nonalcoholic fatty liver disease in rats by activating the AMPK pathway
Askar, M. E., Ali, S. I., Younis, N. N., Shaheen, M. A., & Zaher, M. E. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176001 · Cited by 10
Yiew, N. K. H., Deja, S., Ferguson, D., Cho, K., Jarasvaraparn, C., Jácome-Sosa, M., Lutkewitte, A. J., Mukherjee, S. K., Fu, X., Singer, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108196 · Cited by 9
Chondronikola, M., & Sarkar, S. (2020) · PET Clinics · doi:10.1016/j.cpet.2020.09.001 · Cited by 13
Self-citationKattapuram, N., Zhang, C., Muyyarikkandy, M. S., Surugihalli, C., Muralidaran, V., Gregory, T., & Sunny, N. E. (2021) · Metabolites · doi:10.3390/metabo11050272 · Cited by 11
“Thus, the high-fat diet-induced pathophysiology of NAFLD in rodent models occurs without any increase in de novo lipogenesis, which is a major component in the etiology of human NAFLD [13,37].”
BackgroundBurmese pythons exhibit a transient adaptation to nutrient overload that prevents liver damage
Magida, J. A., Tan, Y., Wall, C. E., Harrison, B. C., Marr, T. G., Peter, A. K., Riquelme, C. A., & Leinwand, L. A. (2022) · The Journal of General Physiology · doi:10.1085/jgp.202113008 · Cited by 11
“Accordingly, severe metabolic perturbations including obesity and type 2 diabetes can lead to permanent hepatic pathologies such as nonalcoholic fatty liver disease (NAFLD; Lonardo et al., 2005).”
Siler, S. Q. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03295-x · Cited by 12
“This submodel mechanistically interacts with the other NAFLDsym sub-models in the following ways: Reduced food intake acta to diminish substrate availability for hepatic de novo lipogenesis and adipose fatty acid release rates are reduced as fat mass is decreased (38, 42, 109).”
MethodAssociations between low‐carbohydrate and low‐fat diets and hepatic steatosis
Li, X., Li, M., Xu, L., Zeng, X., Zhang, T., Hu, Y., Li, H., Zhou, Z., Wang, Y., Zhang, C., et al. (2022) · Obesity · doi:10.1002/oby.23551 · Cited by 12
“Carbohydrates, especially those from refined grains, can increase insulin secretion and glucose concentration, which may promote hepatic de novo lipogenesis [40].”
BackgroundWillis, S. A., Malaikah, S., Bawden, S. J., Sherry, A. P., Sargeant, J. A., Coull, N. A., Bradley, C. R., Rowlands, A., Naim, I., Ennequin, G., et al. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15755 · Cited by 9
“These findings corroborate previous studies reporting elevated saturated hepatic lipids in populations with MASLD, type 2 diabetes, and obesity with high versus low HOMA-IR.”
InfluentialYang, S., Chen, L., Luo, D., Wang, Y.-Y., & Liang, F.-X. (2024) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2024.08.004 · Cited by 10
Transcriptional Regulation of De Novo Lipogenesis by SIX1 in Liver Cancer Cells
Li, L., Zhang, X., Xu, G., Xue, R., Li, S., Wu, S., Yang, Y., Lin, Y., Lin, J., Liu, G., et al. (2024) · Advanced Science · doi:10.1002/advs.202404229 · Cited by 22
Camacho‐Morales, A., Noriega, L. G., Sánchez‐García, A., Torre-Villalvazo, I., Vázquez-Manjarrez, N., Maldonado‐Ruiz, R., Cárdenas‐Tueme, M., Villegas-Romero, M., Alamilla-Martínez, I., Rodríguez‐Rocha, H., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39206 · Cited by 10
LaPoint, A., Singer, J., Ferguson, D., Shew, T. M., Renkemeyer, M. K., Palacios, H. H., Field, R. L., Yerrathota, S., Kumari, R., Shankaran, M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci169722 · Cited by 16
Self-citationPutranata, H., Hengky, A., & Hartoko, B. (2025) · Acta Diabetologica · doi:10.1007/s00592-024-02440-9 · Cited by 10
“This, in turn, impairs gly-cogenesis and promotes gluconeogenesis and glycogenolysis, further exacerbating hyperglycemia [65].”
BMI trajectories are associated with NAFLD and advanced fibrosis via aging-inflammation mediation
Peng, H., Zhao, Z., Gong, J.-P., & He, K. (2025) · BMC Public Health · doi:10.1186/s12889-025-21322-5 · Cited by 14
“Obesity initiates the development of metabolic syndrome, subsequently promoting insulin resistance, thus fostering the occur - rence and progression of NAFLD [20].”
Westerbeke, F. H. M., Ríos-Morales, M., Attaye, I., & Nieuwdorp, M. (2025) · The Journal of Physiology · doi:10.1113/jp287316 · Cited by 11
Zhang, Q., Liu, Z., Zhang, J., Yang, S., & Liu, L. (2025) · Scientific Reports · doi:10.1038/s41598-024-84917-9 · Cited by 11
Metadata
- Authors
- Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., Sirlin, C. B., Talukdar, S., Hellerstein, M. K., & Klein, S.
- Affiliations
- Washington University in St. Louis (US)
- University of California, Berkeley (US)
- University of California San Diego (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Klein, Samuel
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2020-02-04
- Volume
- 130
- Issue
- 3
- Pages
- 1453-1460
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7269561
- OpenAlex
- W2993862932
- Cited by
- 771
- References
- 65
- Citations by year
- 2026: 121 · 2025: 136 · 2024: 153 · 2023: 123 · 2022: 104 · 2021: 92 · 2020: 40
- FWCI
- 44.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (DK56341,DK20579,DK52574,RR024992)
- College of Natural Resources, University of California at Berkeley (N/A)
- Pershing Square Foundation (N/A)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, hepatic de novo lipogenesis, insulin resistance, intrahepatic triglyceride, hepatic insulin sensitivity, weight loss, obesity, hepatic steatosis, plasma glucose, hyperinsulinemic-euglycemic clamp
- MeSH terms
- Adult, Blood Glucose, Female, Humans, Insulin, Insulin Resistance, Liver, Male, Triglycerides, Palmitic Acid, Lipogenesis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.